Immunocore Updates Brenetafusp Clinical Trial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 hours ago
0mins
Immunocore announced updated results from its Phase 1/2 trial evaluating brenetafusp in patients with heavily pretreated advanced melanoma. The data is presented in a poster at the 2026 American Society of Clinical Oncology, ASCO, Annual Meeting. In the 66 patients treated with brenetafusp monotherapy, the median overall survival was 14.3 months with a landmark OS rate of 87% at 6 months and 57% at 12 months. The disease control rate was 52%, while the overall response rate was 12%. Multiple measures of clinical benefit were numerically higher for patients treated with the 160 mcg dose - despite worse baseline prognostic factors compared to those treated with 40 mcg. These data support selection of 160 mcg for the ongoing Phase 3 trial evaluating brenetafusp + nivolumab vs. standard nivolumab regimens in first-line advanced melanoma. The safety profile was similar at both doses. Brenetafusp was generally well tolerated, showing a predictable, mechanism-driven safety profile as monotherapy and in combination.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMCR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMCR
Wall Street analysts forecast IMCR stock price to rise
9 Analyst Rating
7 Buy
2 Hold
0 Sell
Strong Buy
Current: 28.970
Low
37.00
Averages
64.56
High
100.00
Current: 28.970
Low
37.00
Averages
64.56
High
100.00
About IMCR
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immunocore Updates Phase 1 Data on Brenetafusp for Advanced Melanoma
- Significant Survival Rates: Among 66 patients treated with brenetafusp monotherapy, the 6-month overall survival rate reached 87%, with a 12-month survival rate of 57%, indicating the drug's potential efficacy in heavily pretreated melanoma patients and offering new treatment options.
- Dose Selection Support: Data indicates that the 160 mcg dose exhibited a higher disease control rate of 52%, providing strong support for the ongoing Phase 3 PRISM-MEL-301 trial aimed at evaluating the efficacy of brenetafusp in combination with nivolumab.
- Good Tolerability: Brenetafusp demonstrated good tolerability both as monotherapy and in combination with pembrolizumab, with common adverse events including low-grade cytokine release syndrome (56%) and rash (44%), indicating a manageable safety profile that supports future clinical applications.
- Efficacy in Refractory Patients: Even in patients with primary PD-1 resistance, the median overall survival with brenetafusp reached 14.7 months, highlighting its potential clinical benefits in difficult-to-treat melanoma patients and possibly changing the treatment landscape in this area.
See More
Immunocore Updates Phase 1 Data on Brenetafusp for Advanced Melanoma
- Significant Survival Rates: In 66 heavily pretreated patients with advanced melanoma receiving brenetafusp monotherapy, the 6-month overall survival rate reached 87%, indicating the drug's potential to transform treatment options for difficult-to-treat patients.
- Dose Selection Support: Data indicate that the 160 mcg dose exhibited a higher disease control rate of 52%, providing robust support for the ongoing Phase 3 PRISM-MEL-301 trial, which may enhance first-line treatment outcomes.
- Good Tolerability: Brenetafusp demonstrated favorable tolerability both as monotherapy and in combination with pembrolizumab, with common adverse events including low-grade cytokine release syndrome (56%) and rash (44%), instilling confidence in its clinical application.
- Consistent Clinical Benefits: Brenetafusp showed consistent survival rates (median OS of 14.7 months) even in patients with primary PD-1 resistance, highlighting its potential value in refractory patients and suggesting new directions for future treatment strategies.
See More
Black Diamond Therapeutics Shares Plunge 35.8% Amid Mixed Phase II Results
- Clinical Trial Results: Black Diamond Therapeutics reported a preliminary median progression-free survival (mPFS) of 15.2 months for its phase II trial of silevertinib in NSCLC patients with EGFR non-classical mutations, yet the stock plummeted 35.8% as investors expressed concerns over the early nature of the data and modest patient count.
- Patient Data Analysis: The study enrolled 43 patients treated with a 200 mg dose of silevertinib, with 53% remaining on therapy at the data cutoff, and the longest treatment duration reaching 23.5 months, indicating potential durability of responses, although longer follow-up is needed to clarify the final benefit-risk profile.
- CNS Activity: Silevertinib demonstrated an 86% objective response rate in the central nervous system (CNS), with no new brain metastases reported by the cutoff date, suggesting this profile could be pivotal for the company's development and regulatory strategy, particularly if maintained in larger datasets.
- Safety Management: No new safety signals were observed, but severe treatment-related adverse events decreased to 28% after dose reduction, supporting the decision to adjust the dose to 150 mg; however, the need for dose optimization may have contributed to the negative market reaction.
See More
Immunocore Q1 Earnings Beat Expectations
- Earnings Beat: Immunocore reported a Q1 GAAP EPS of $0.25, exceeding expectations by $0.47, indicating strong profitability that may boost investor confidence in the company's financial health.
- Revenue Miss: The revenue of $106.68 million, while up 13.6% year-over-year, fell short of expectations by $3.7 million, reflecting increased market competition and sales challenges that could impact future growth outlook.
- Strong Cash Position: As of March 31, 2026, Immunocore held $844.9 million in cash, cash equivalents, and marketable securities, providing financial flexibility for R&D and operations, which supports long-term strategic initiatives.
- Positive Market Reaction: Despite the revenue miss, the earnings beat may lead to a short-term stock price increase, as investors remain optimistic about the company's growth potential, particularly in the context of ongoing innovation in the biopharmaceutical sector.
See More
Immunocore Holdings Shares Show Oversold Signal
- Oversold Indicator Analysis: Immunocore Holdings PLC's relative strength index (RSI) has dropped to 29.5, indicating that the stock has entered oversold territory, which may attract bullish investors looking for buying opportunities, reflecting that the recent heavy selling is gradually exhausting.
- Price Fluctuation Details: The company's stock price hit a low of $28.435, with the current trading price at $28.56, only $1.12 above the 52-week low of $27.44, indicating market interest and potential rebound opportunities for the stock.
- Market Comparison Analysis: Compared to the current RSI of 68.0 for the S&P 500 ETF (SPY), IMCR's low RSI value may suggest that its relative value is undervalued, prompting investors to consider increasing their positions to capture future rebounds.
- Historical Performance Review: IMCR's 52-week high stands at $40.7147, and the current stock price shows a significant gap from this peak, reflecting fluctuations in market confidence that may provide potential buying opportunities for investors.
See More
KIMMTRAK Doubles Five-Year Survival Rate for Metastatic Uveal Melanoma Patients
- Survival Rate Improvement: KIMMTRAK has achieved a five-year survival rate of 16% in HLA-A*02:01 positive metastatic uveal melanoma patients, doubling the rate of the control group, demonstrating its significant impact on patient prognosis.
- Clinical Trial Data: In a randomized trial involving 378 patients, the median overall survival for the KIMMTRAK group was 21.6 months, significantly surpassing the 16.9 months observed in the control group, indicating the drug's potential in extending survival.
- Treatment Continuation: In the KIMMTRAK group, 57% of patients continued treatment beyond disease progression compared to only 25% in the control group, highlighting the drug's tolerability and the willingness of patients to continue therapy.
- Prognostic Factor Impact: KIMMTRAK demonstrated survival benefits even in patients with known poor prognostic factors such as high tumor burden and elevated LDH, further solidifying its position as a first-line treatment.
See More
Immunocore Updates Phase 1 Data on Brenetafusp for Advanced Melanoma
- Significant Survival Rates: Among 66 patients treated with brenetafusp monotherapy, the 6-month overall survival rate reached 87%, with a 12-month survival rate of 57%, indicating the drug's potential efficacy in heavily pretreated melanoma patients and offering new treatment options.
- Dose Selection Support: Data indicates that the 160 mcg dose exhibited a higher disease control rate of 52%, providing strong support for the ongoing Phase 3 PRISM-MEL-301 trial aimed at evaluating the efficacy of brenetafusp in combination with nivolumab.
- Good Tolerability: Brenetafusp demonstrated good tolerability both as monotherapy and in combination with pembrolizumab, with common adverse events including low-grade cytokine release syndrome (56%) and rash (44%), indicating a manageable safety profile that supports future clinical applications.
- Efficacy in Refractory Patients: Even in patients with primary PD-1 resistance, the median overall survival with brenetafusp reached 14.7 months, highlighting its potential clinical benefits in difficult-to-treat melanoma patients and possibly changing the treatment landscape in this area.
See More
Immunocore Updates Phase 1 Data on Brenetafusp for Advanced Melanoma
- Significant Survival Rates: In 66 heavily pretreated patients with advanced melanoma receiving brenetafusp monotherapy, the 6-month overall survival rate reached 87%, indicating the drug's potential to transform treatment options for difficult-to-treat patients.
- Dose Selection Support: Data indicate that the 160 mcg dose exhibited a higher disease control rate of 52%, providing robust support for the ongoing Phase 3 PRISM-MEL-301 trial, which may enhance first-line treatment outcomes.
- Good Tolerability: Brenetafusp demonstrated favorable tolerability both as monotherapy and in combination with pembrolizumab, with common adverse events including low-grade cytokine release syndrome (56%) and rash (44%), instilling confidence in its clinical application.
- Consistent Clinical Benefits: Brenetafusp showed consistent survival rates (median OS of 14.7 months) even in patients with primary PD-1 resistance, highlighting its potential value in refractory patients and suggesting new directions for future treatment strategies.
See More
Black Diamond Therapeutics Shares Plunge 35.8% Amid Mixed Phase II Results
- Clinical Trial Results: Black Diamond Therapeutics reported a preliminary median progression-free survival (mPFS) of 15.2 months for its phase II trial of silevertinib in NSCLC patients with EGFR non-classical mutations, yet the stock plummeted 35.8% as investors expressed concerns over the early nature of the data and modest patient count.
- Patient Data Analysis: The study enrolled 43 patients treated with a 200 mg dose of silevertinib, with 53% remaining on therapy at the data cutoff, and the longest treatment duration reaching 23.5 months, indicating potential durability of responses, although longer follow-up is needed to clarify the final benefit-risk profile.
- CNS Activity: Silevertinib demonstrated an 86% objective response rate in the central nervous system (CNS), with no new brain metastases reported by the cutoff date, suggesting this profile could be pivotal for the company's development and regulatory strategy, particularly if maintained in larger datasets.
- Safety Management: No new safety signals were observed, but severe treatment-related adverse events decreased to 28% after dose reduction, supporting the decision to adjust the dose to 150 mg; however, the need for dose optimization may have contributed to the negative market reaction.
See More
Immunocore Q1 Earnings Beat Expectations
- Earnings Beat: Immunocore reported a Q1 GAAP EPS of $0.25, exceeding expectations by $0.47, indicating strong profitability that may boost investor confidence in the company's financial health.
- Revenue Miss: The revenue of $106.68 million, while up 13.6% year-over-year, fell short of expectations by $3.7 million, reflecting increased market competition and sales challenges that could impact future growth outlook.
- Strong Cash Position: As of March 31, 2026, Immunocore held $844.9 million in cash, cash equivalents, and marketable securities, providing financial flexibility for R&D and operations, which supports long-term strategic initiatives.
- Positive Market Reaction: Despite the revenue miss, the earnings beat may lead to a short-term stock price increase, as investors remain optimistic about the company's growth potential, particularly in the context of ongoing innovation in the biopharmaceutical sector.
See More
Immunocore Holdings Shares Show Oversold Signal
- Oversold Indicator Analysis: Immunocore Holdings PLC's relative strength index (RSI) has dropped to 29.5, indicating that the stock has entered oversold territory, which may attract bullish investors looking for buying opportunities, reflecting that the recent heavy selling is gradually exhausting.
- Price Fluctuation Details: The company's stock price hit a low of $28.435, with the current trading price at $28.56, only $1.12 above the 52-week low of $27.44, indicating market interest and potential rebound opportunities for the stock.
- Market Comparison Analysis: Compared to the current RSI of 68.0 for the S&P 500 ETF (SPY), IMCR's low RSI value may suggest that its relative value is undervalued, prompting investors to consider increasing their positions to capture future rebounds.
- Historical Performance Review: IMCR's 52-week high stands at $40.7147, and the current stock price shows a significant gap from this peak, reflecting fluctuations in market confidence that may provide potential buying opportunities for investors.
See More
KIMMTRAK Doubles Five-Year Survival Rate for Metastatic Uveal Melanoma Patients
- Survival Rate Improvement: KIMMTRAK has achieved a five-year survival rate of 16% in HLA-A*02:01 positive metastatic uveal melanoma patients, doubling the rate of the control group, demonstrating its significant impact on patient prognosis.
- Clinical Trial Data: In a randomized trial involving 378 patients, the median overall survival for the KIMMTRAK group was 21.6 months, significantly surpassing the 16.9 months observed in the control group, indicating the drug's potential in extending survival.
- Treatment Continuation: In the KIMMTRAK group, 57% of patients continued treatment beyond disease progression compared to only 25% in the control group, highlighting the drug's tolerability and the willingness of patients to continue therapy.
- Prognostic Factor Impact: KIMMTRAK demonstrated survival benefits even in patients with known poor prognostic factors such as high tumor burden and elevated LDH, further solidifying its position as a first-line treatment.
See More
